Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of an educational grant from Bayer plc.
Stable peripheral arterial disease guideline
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.
Stable coronary artery disease guideline
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
SIGN antithrombotics guideline
A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.
Resource hub
Practical guide to recording ankle brachial pressure index (ABPI)
- Previous
- Next
Educational resources
Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
PP-XAR-GB-2051 April 2021
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.
PP-XAR-GB-2053 April 2021
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Information intended for healthcare professionals only.
View prescribing information and adverse event reporting information
*Rivaroxaban is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.
PP-XAR-GB-2052 April 2021
The holistic management of patients requiring anticoagulation
This video has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View Xarelto▼(rivaroxaban) prescribing information and adverse event reporting
PP-XAR-GB-1924 January 2021
Modern management of venous thromboembolism in primary care
These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS − Pfizer Alliance and developed in conjunction with Guidelines. The promotional content on this page is intended for UK healthcare professionals only.
View Eliquis (apixaban) prescribing and adverse event reporting information
432-GB-2100016
Date of preparation: February 2021